01
Capital architecture
Scientific teams often reach a point where progress is real, but the pathway into a selective Series A round is still fragile.
From validated science to human impact
Break the science fair.
We pair capital with commercialization to move valuable intellectual property beyond the lab and into the world.
FundSelective Series A in healthcare and life sciences
AdvisoryCommercialization across IP-rich sectors
One problem. Two pathways.
HHP
Scientific progress needs a commercial pathway.
Fund
Selective Series A
Healthcare and life sciences companies with validated science.
Advisory
IP Commercialization
University, laboratory, and founder-led innovation across sectors.
The strongest science can still stall when market ownership, operating readiness, and capital strategy are not built in step.
Where promising science stalls
The problem is rarely the science.
Commercialization breaks down when technical progress is not matched by market ownership, operating discipline, aligned people, and the right sequence of capital. That problem is consistent across healthcare, engineering, climate, materials, and other IP-rich disciplines.
02
Commercial readiness
Great science does not automatically translate into product definition, reimbursement logic, go-to-market clarity, or operational sequencing.
03
Human alignment
Founders, clinicians, researchers, and investors frequently optimize for different timelines and different definitions of success.
04
Execution support
Many companies do not need generic advice. They need precise support at the moments that determine whether the company becomes fundable and buildable.
Fund
We invest in selective healthcare and life sciences opportunities where validated science needs the right capital architecture and commercialization support to move forward.
- Selective Series A investment focus
- Selective, domain-aware conviction
- Focus on commercial readiness and translational progress
- Built for companies crossing the gap between science and market
Advisory
We help scientific founders, institutions, and strategic partners commercialize intellectual property across sectors by strengthening the operating, commercial, and partnership systems around it.
- Commercialization strategy for university and research IP
- Capital readiness and partner positioning
- Expert network activation and execution support
- Cross-sector institutional and venture-building advisory
How we work
A commercialization framework with operating depth.
Human Health Platform applies the same commercialization framework across IP categories, helping teams move from promising science to investable, buildable, and partner-ready companies.
Assess
Understand the science, the team, the market logic, and the commercialization bottlenecks that matter most.
Architect
Shape the capital, product, and operating pathway needed for the next phase of company development.
Align
Clarify incentives, roles, and decision pathways across founders, experts, and stakeholders.
Activate
Bring in the right commercialization, scientific, and strategic support at key execution moments.
Advance
Help companies move toward partnership, financing, and durable commercial progress.
Human alignment
The people behind the science are part of the commercialization system.
The strongest strategy can still fail when the people responsible for executing it are working toward different outcomes.
Scientific founders are often asked to become CEOs overnight. Universities assemble multidisciplinary teams that may never have worked together. Investors, clinicians, engineers, and researchers frequently optimize for different timelines and definitions of success. Commercialization becomes possible when those perspectives align around a shared operating framework.
A
Founder translation
Support scientific founders as they move from technical depth toward capital, product, and commercial storytelling.
B
Stakeholder alignment
Clarify roles, expectations, and incentives across institutional, commercial, and venture stakeholders.
C
Decision pacing
Create sharper sequencing so teams know what must happen now, later, and not yet.
D
Execution rhythm
Translate complexity into actions that can be owned, measured, and advanced.
Human health is our investment focus because the impact is immediate and measurable. Our advisory work applies the same commercialization discipline across sectors, helping exceptional people translate specialized knowledge and defensible IP into meaningful progress.
01The people
Human
The people behind the science determine whether the science ultimately reaches people.
02The focus
Health
Healthcare is where we focus our capital because the consequences—and the opportunity for measurable impact—are immediate.
03The system
Platform
Capital, commercialization, and expertise work together as one operating framework rather than independently.
Investment focus
Focused by domain. Built for translation.
Human Health Platform’s investment activity is focused on healthcare and life sciences, where the commercial and capital pathway matters as much as the scientific promise. Advisory engagements extend across sectors and IP categories.
Healthcare
Life Sciences
Diagnostics
Medical Devices
Biotech Enablement
Commercialization Readiness
Advisory scope: university and founder-led IP across scientific and technical disciplines.
What we look for
We are most useful when science is credible, the problem matters, and the company needs a sharper bridge into commercial execution.
Validated scienceReal technical insight or differentiated intellectual property.
Clear unmet needProblems with real clinical, commercial, or system-level relevance.
Translational opportunityPotential to move from research-stage promise toward market readiness.
Execution inflection pointA stage where the right capital and support can materially change the outcome.
Leadership & network
The platform is led by builders, operators, and commercialization partners.
Human Health Platform combines capital markets perspective, venture-building support, commercialization strategy, and an activated network of advisors across science, healthcare, and company building.
Leadership
The core team combines capital, commercialization, and operating support.
The Human Health Platform leadership team brings complementary strengths across investment experience, go-to-market thinking, strategic execution, and portfolio support for science-driven ventures.
15+Years of investment, operating, and strategic advisory experience across the leadership platform
$1B+In mergers and acquisitions advised by HHP founder Stephen Ippolito
Selective Series AFocused investment orientation for validated science companies ready for institutional growth
Cross-functionalCapital, commercialization, portfolio operations, and venture support
Founder & Managing Partner, Veritus Holdings
Stephen Ippolito
Stephen Ippolito brings more than 15 years across investment banking, growth equity, and operating leadership. He has advised on over $1 billion in M&A, co-founded The Seed Lab, and launched Human Health Platform to help validated science cross the gap from promising company to durable enterprise.
Venture Partner, Commercialization & Go-to-Market
Dhairya Pujara
Dhairya Pujara works across commercialization, venture building, and go-to-market strategy. Drawing on experience in healthcare, entrepreneurship, and innovation, he helps science-driven founders define market pathways, align stakeholders, and translate specialized knowledge into products, partnerships, and measurable commercial progress.
Venture Partner, Finance & Portfolio Operations
Chris Ippolito
Chris Ippolito supports finance, portfolio operations, and company execution across Human Health Platform. He helps science-driven ventures strengthen financial visibility, capital planning, operating discipline, and decision-making as they move from technical validation toward commercial readiness and institutional growth.
Advisors & expert network
A curated network across scientific, clinical, commercialization, and operating expertise.
Human Health Platform works with a curated network of clinical, scientific, commercialization, and operating experts who support companies and institutional initiatives at key moments of development.
Advisor
James J. Chao, MD, FACS
Physician-entrepreneur and healthcare operator with experience across clinical innovation, practice building, and venture creation in healthcare delivery.
Scientific / Clinical Advisor
Wilbur A. Lam, MD, PhD
W. Paul Bowers Research Chair and Professor at Emory and Georgia Tech, pediatric hematologist/oncologist, and innovation leader focused on microsystems, microfluidics, and patient-operated diagnostics.
Commercialization Advisor
Stacy Chick
Life sciences operator, commercialization consultant, and advisor who has helped transform research-stage companies into commercial entities through financing, partnerships, and execution leadership.
Venture Expert Network
Mike Cremeans
Life sciences risk and insurance strategist advising FDA-regulated businesses and investors across medtech, pharma, biotech, and medical device transactions.
Looking at science through a commercialization lens?
We work with selective founders, institutions, and strategic partners who are serious about translating validated science into real-world progress.